MediWound posts investor presentation on enzymatic burn and chronic-wound therapies NexoBrid, EscharEx

Reuters2026/08/13 11:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MediWound outlined a growth plan centered on NexoBrid, marketed for severe burn eschar removal, with 2025 revenue of USD 17 million.
EscharEx, an investigational chronic-wound debridement therapy, targets a USD 4 billion U.S. market; VLU program in Phase 3.
Company highlighted a cash balance of USD 36 million with no debt; cited runway through profitability.
Presentation flagged potential additional proceeds of up to USD 29 million from Series A warrant exercises expiring in November 2026.
New cGMP sterile manufacturing facility designed to expand capacity sixfold; regulatory approvals expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

MediWound posts investor presentation on enzymatic burn and chronic-wound therapies NexoBrid, EscharEx

You may also like

Crypto prices